Advancing HCC Trial Design with Targeted PET Tracers and LI-RADS, RECIST/mRECIST
Hepatocellular carcinoma (HCC) is not just a leading cause of cancer deaths but also has rising mortality and frequent resistance to therapy. Accurate staging and early detection directly influence eligibility for curative options and downstream outcomes. In clinical trials, integrating… Read More